These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 26968141)
1. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141 [TBL] [Abstract][Full Text] [Related]
2. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type. Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821 [TBL] [Abstract][Full Text] [Related]
4. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Youk JH; Son EJ; Chung J; Kim JA; Kim EK Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371 [TBL] [Abstract][Full Text] [Related]
5. DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers. Fan M; Cheng H; Zhang P; Gao X; Zhang J; Shao G; Li L J Magn Reson Imaging; 2018 Jul; 48(1):237-247. PubMed ID: 29219225 [TBL] [Abstract][Full Text] [Related]
6. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes. Bae MS; Seo M; Kim KG; Park IA; Moon WK Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165 [TBL] [Abstract][Full Text] [Related]
7. Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer. Ma M; Gan L; Jiang Y; Qin N; Li C; Zhang Y; Wang X Comput Math Methods Med; 2021; 2021():2140465. PubMed ID: 34422088 [TBL] [Abstract][Full Text] [Related]
8. Computer-based automated estimation of breast vascularity and correlation with breast cancer in DCE-MRI images. Kostopoulos SA; Vassiou KG; Lavdas EN; Cavouras DA; Kalatzis IK; Asvestas PA; Arvanitis DL; Fezoulidis IV; Glotsos DT Magn Reson Imaging; 2017 Jan; 35():39-45. PubMed ID: 27569368 [TBL] [Abstract][Full Text] [Related]
9. Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes. Yang Q; Liu HY; Liu D; Song YQ Asian Pac J Cancer Prev; 2015; 16(8):3229-32. PubMed ID: 25921124 [TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis. Chaudhury B; Zhou M; Goldgof DB; Hall LO; Gatenby RA; Gillies RJ; Patel BK; Weinfurtner RJ; Drukteinis JS J Magn Reson Imaging; 2015 Nov; 42(5):1421-30. PubMed ID: 25884277 [TBL] [Abstract][Full Text] [Related]
11. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Agner SC; Rosen MA; Englander S; Tomaszewski JE; Feldman MD; Zhang P; Mies C; Schnall MD; Madabhushi A Radiology; 2014 Jul; 272(1):91-9. PubMed ID: 24620909 [TBL] [Abstract][Full Text] [Related]
12. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer. Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114 [TBL] [Abstract][Full Text] [Related]
13. Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI. Xu WJ; Zheng BJ; Lu J; Liu SY; Li HL BMC Med Imaging; 2023 Jun; 23(1):70. PubMed ID: 37264313 [TBL] [Abstract][Full Text] [Related]
14. Can imaging kinetic parameters of dynamic contrast-enhanced magnetic resonance imaging be valuable in predicting clinicopathological prognostic factors of invasive breast cancer? Wang C; Wei W; Santiago L; Whitman G; Dogan B Acta Radiol; 2018 Jul; 59(7):813-821. PubMed ID: 29105486 [TBL] [Abstract][Full Text] [Related]
15. Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. Grimm LJ; Zhang J; Mazurowski MA J Magn Reson Imaging; 2015 Oct; 42(4):902-7. PubMed ID: 25777181 [TBL] [Abstract][Full Text] [Related]
16. Computer-aided diagnosis of breast DCE-MRI using pharmacokinetic model and 3-D morphology analysis. Wang TC; Huang YH; Huang CS; Chen JH; Huang GY; Chang YC; Chang RF Magn Reson Imaging; 2014 Apr; 32(3):197-205. PubMed ID: 24439361 [TBL] [Abstract][Full Text] [Related]
17. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583 [TBL] [Abstract][Full Text] [Related]
18. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer molecular subtype classifier that incorporates MRI features. Sutton EJ; Dashevsky BZ; Oh JH; Veeraraghavan H; Apte AP; Thakur SB; Morris EA; Deasy JO J Magn Reson Imaging; 2016 Jul; 44(1):122-9. PubMed ID: 26756416 [TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors. Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]